| Followers | 250 |
| Posts | 14020 |
| Boards Moderated | 3 |
| Alias Born | 07/07/2006 |
Tuesday, January 10, 2012 1:29:12 AM
THLD dec 13th presentation slides Check 2nd slide for IIb pancreatic cancer final data release date.
At 1.50 it has a ~70mln market cap.
On their compound (ongoign trials)
TH-302 http://clinicaltrials.gov/ct2/results?term=th-302
Smallcap cancer company.
Solid tumors.
First line for pancreatic cancer trial results ( IIb )due mid february.
http://www.thresholdpharm.com/
I think its a good value proposition here on current market cap.
"As part of the update, the Company will provide guidance that it now expects to report the primary analysis of the TH-302 Phase 2 pancreatic data in mid- to late February of 2012. Threshold completed enrollment of this trial as scheduled in June 2011 with the enrollment of 214 patients, but it has taken longer to reach the 144 progression free survival (PFS) events that are required to trigger the primary analysis than originally anticipated. Over 90% of the 144 events planned for the primary analysis have occurred to date. "With respect to those aspects of this trial under our control, we have executed on or ahead of schedule and were actually able to increase the size and statistical power of this trial, in large part due to investigator and patient interest," said Barry Selick, Chief Executive Officer. "What we cannot control is the rate at which patients progress, but we are now far enough along in the study to be confident that we will be able to report the results of the trial in February."
The Phase 2 trial is a multi-center, randomized, controlled, crossover clinical trial of TH-302 in combination with gemcitabine in patients with first line pancreatic cancer. The primary endpoint of the trial is progression-free survival. The secondary endpoints are overall response rate, overall survival, event-free survival, CA 19-9 response rate as well as various safety parameters. Tumor response is evaluated at baseline and every eight weeks using RECIST. Patients for whom monotherapy with gemcitabine is considered standard therapy were eligible for the trial. Patients were randomized equally into one of three cohorts: TH-302 at a dose of 240 mg/m2 plus gemcitabine, TH-302 at a dose of 340 mg/m2 plus gemcitabine, or gemcitabine alone. Patients who successfully complete six cycles of treatment without evidence of significant treatment-related toxicity or progressive disease could continue to receive treatment. If a patient experienced cancer progression on gemcitabine alone, the patient could cross over into one of the TH-302 plus gemcitabine cohorts. The primary efficacy analysis will be performed based upon approximately 144 PFS events.
"
At 1.50 it has a ~70mln market cap.
On their compound (ongoign trials)
TH-302 http://clinicaltrials.gov/ct2/results?term=th-302
Smallcap cancer company.
Solid tumors.
First line for pancreatic cancer trial results ( IIb )due mid february.
http://www.thresholdpharm.com/
I think its a good value proposition here on current market cap.
"As part of the update, the Company will provide guidance that it now expects to report the primary analysis of the TH-302 Phase 2 pancreatic data in mid- to late February of 2012. Threshold completed enrollment of this trial as scheduled in June 2011 with the enrollment of 214 patients, but it has taken longer to reach the 144 progression free survival (PFS) events that are required to trigger the primary analysis than originally anticipated. Over 90% of the 144 events planned for the primary analysis have occurred to date. "With respect to those aspects of this trial under our control, we have executed on or ahead of schedule and were actually able to increase the size and statistical power of this trial, in large part due to investigator and patient interest," said Barry Selick, Chief Executive Officer. "What we cannot control is the rate at which patients progress, but we are now far enough along in the study to be confident that we will be able to report the results of the trial in February."
The Phase 2 trial is a multi-center, randomized, controlled, crossover clinical trial of TH-302 in combination with gemcitabine in patients with first line pancreatic cancer. The primary endpoint of the trial is progression-free survival. The secondary endpoints are overall response rate, overall survival, event-free survival, CA 19-9 response rate as well as various safety parameters. Tumor response is evaluated at baseline and every eight weeks using RECIST. Patients for whom monotherapy with gemcitabine is considered standard therapy were eligible for the trial. Patients were randomized equally into one of three cohorts: TH-302 at a dose of 240 mg/m2 plus gemcitabine, TH-302 at a dose of 340 mg/m2 plus gemcitabine, or gemcitabine alone. Patients who successfully complete six cycles of treatment without evidence of significant treatment-related toxicity or progressive disease could continue to receive treatment. If a patient experienced cancer progression on gemcitabine alone, the patient could cross over into one of the TH-302 plus gemcitabine cohorts. The primary efficacy analysis will be performed based upon approximately 144 PFS events.
"
To follow my postings on ihub use this link : Ihub person mark
Feedback is allways appreciated, as are other (annotated) picks
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
